Asthma rescue without needles: nasal spray could replace shots

NCT ID NCT05363670

Completed Disease control Sponsor: ARS Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 2 trial tests a needle-free epinephrine nasal spray (ARS-1) for managing asthma symptoms. People with persistent asthma receive a single dose of ARS-1, albuterol, or placebo in random order. The study measures how well the spray improves lung function compared to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a needle-free epinephrine nasal spray called ARS-1
What this could lead to: If successful, this could offer a needle-free way to quickly treat asthma attacks, making emergency epinephrine easier to use.
What could go wrong: This is an early phase 2 trial with only 18 participants, so results may not apply to everyone. The spray may not work as well as injected epinephrine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Show contact details

Locations

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, 45236, United States
Institute for Asthma and Allergy

Chevy Chase, Maryland, 20815, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of South Florida

Tampa, Florida, 33613, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.